AR004225A1 - Derivados de indolin-2-ona, su uso, un procedimiento para prepararlos, composiciones farmaceuticas que los comprenden y compuestos utiles como intermediarios para preparar dichos derivados - Google Patents

Derivados de indolin-2-ona, su uso, un procedimiento para prepararlos, composiciones farmaceuticas que los comprenden y compuestos utiles como intermediarios para preparar dichos derivados

Info

Publication number
AR004225A1
AR004225A1 ARP960104863A ARP960104863A AR004225A1 AR 004225 A1 AR004225 A1 AR 004225A1 AR P960104863 A ARP960104863 A AR P960104863A AR P960104863 A ARP960104863 A AR P960104863A AR 004225 A1 AR004225 A1 AR 004225A1
Authority
AR
Argentina
Prior art keywords
alkyl
derivatives
prepare
group
indolin
Prior art date
Application number
ARP960104863A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR004225A1 publication Critical patent/AR004225A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a derivados de indolin-2-ona caracterizados porque responden a la fórmula (I), en la cual:R1 y R2representan cada uno independientemente un H; un hidroxilo, un halógeno, un (C1-C7)alquilo, un(C1-C7) polifluoroalquilo, un (C1-C7)alcoxi, un (C1-C7)alquiltio, un (C1-C7)polifluoroalcoxi, un (C1-C7)cicloalquiloxi, un C3-C7) cicloalquiltio, un cicloalquilmetoxi o un cicloalquilmetiltio en los cuales elcicloalquilo C3-C7, un fenoxi, unbenciloxi, un nitro, un ciano; R3 y R4 independientemente uno del otro substituyen una o varias veces el grupofenilo y representan cada uno independientemente H, halógeno, (C1-C7) alquilo, un (C2-C7)alquenilo, un(C1-C7)polihalogenoalquil; u n fenilo o unbencilo, ciano, nitro, -NR5R9, hidroxiamino, hidroxi, -OR7, SR7, -COOR9, -CONR9R10, -CSNR4R10 siendo al menos uno de los radicales R3 y R4diferente del H; W representa un grupo -CH2- -SO2-; Cyconstituye, con el carbono a l cual está ligado, un ciclo hidrocarbonado no aromático enC3-C12, saturado o insaturado, eventualmente condensado o substituido por uno o varios grupos (C1-C7)alquilos, pudiendo los mencionadosgrupossubstituir una o varias veces el mismo átomo de carbono por espirocicloalquilo en C3-C4; T representa un (C1-C4)alquileno eventualmenteinterrumpido por un (C3-C4)cicloalquileno, siendo los mencionados alquilenoseventualmente substituidos una o varias veces sobre el mismo átomo de carbonopor un (C1-C3)alquilo, o bien T representa una unión directa; Z representa un -R11R12, - NR11R12(C1-C4)alquilo(A), (A) siendo un anión, de preferenciaCl, Br, I óCH3SO4,-N(O)R11R12; un grupo -COOR11, un grupo -NR11COR12;un gr upo -NR11COR12, un (C1-C4)alquiloxicarbonilamino, un benciloxicarbonilamino; un
ARP960104863A 1995-10-24 1996-10-23 Derivados de indolin-2-ona, su uso, un procedimiento para prepararlos, composiciones farmaceuticas que los comprenden y compuestos utiles como intermediarios para preparar dichos derivados AR004225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9512533A FR2740136B1 (fr) 1995-10-24 1995-10-24 Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
AR004225A1 true AR004225A1 (es) 1998-11-04

Family

ID=9483867

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960104863A AR004225A1 (es) 1995-10-24 1996-10-23 Derivados de indolin-2-ona, su uso, un procedimiento para prepararlos, composiciones farmaceuticas que los comprenden y compuestos utiles como intermediarios para preparar dichos derivados

Country Status (31)

Country Link
US (2) US5994350A (es)
EP (1) EP0873309B1 (es)
JP (2) JP3274471B2 (es)
KR (1) KR100298925B1 (es)
CN (1) CN1106384C (es)
AR (1) AR004225A1 (es)
AT (1) ATE229940T1 (es)
AU (1) AU715841B2 (es)
BR (1) BR9611198A (es)
CZ (1) CZ295585B6 (es)
DE (1) DE69625517T2 (es)
DK (1) DK0873309T3 (es)
EE (1) EE04433B1 (es)
ES (1) ES2191769T3 (es)
FR (1) FR2740136B1 (es)
HK (1) HK1016596A1 (es)
HU (1) HUP9900331A3 (es)
IL (1) IL124002A (es)
IN (1) IN185328B (es)
IS (1) IS1949B (es)
MY (1) MY115864A (es)
NO (1) NO310974B1 (es)
NZ (1) NZ320352A (es)
PL (1) PL187093B1 (es)
RU (1) RU2167864C2 (es)
SK (1) SK284546B6 (es)
TR (1) TR199800719T2 (es)
TW (1) TW474917B (es)
UA (1) UA59345C2 (es)
WO (1) WO1997015556A1 (es)
ZA (1) ZA968945B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2775598A1 (fr) 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
HU225150B1 (en) 1999-07-15 2006-07-28 Sanofi Aventis Novel process for producing 2-methoxy-4-(t-butylaminocarbonyl)-benzenesulfonyl chloride
HUP9902374A3 (en) * 1999-07-15 2002-11-28 Sanofi Aventis Process for producing spiro[(4-cyclohexanone)-[3h]indol-2'[1'h]-on derivatives and intermediates
HU225703B1 (en) * 1999-07-15 2007-06-28 Sanofi Aventis Process for producing spiro[cis-4-(betha-hydroxy-ethyloxi)-cyclohexane-[3h]indole]-2'[1'h]-one derivatives
HUP9902376A3 (en) * 1999-07-15 2002-11-28 Sanofi Aventis Process for producing n-(1,1-dimethyl)-4-[[s'-ethoxi-4-cis-[2-(4-morpholino)-ethoxi]-2'-oxospiro[cyclohexane-1,3'-[3h]indole]-1'(2'h)yl]-sulfonyl]-3-methoxybenzamide and its salts
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
WO2002044179A1 (fr) * 2000-11-28 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de 1,4,5,6-tétrahydroimidazo[4,5-d]diazépine ou sels de ces derniers
US20020128208A1 (en) * 2000-12-15 2002-09-12 Snyder James P. Nonpeptide agonists and antagonists of vasopressin receptors
WO2002064022A2 (en) * 2001-02-14 2002-08-22 Duke University Therapy for cerebral vasospasm
WO2003011827A1 (en) 2001-07-31 2003-02-13 Sanofi-Synthelabo Process for the preparation of 3-spiro'cyclohexam-1,3'-'3h!indolin-2'-one! derivatives
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
FR2874921B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one, leur preparation et leur application en therapeutique
FR2874920B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one comme ligand des recepteurs de la vasopressine
BRPI0519013A2 (pt) * 2004-12-13 2009-11-03 Lilly Co Eli composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
CA2593044A1 (en) * 2004-12-31 2006-07-13 Abbott Gmbh & Co. Kg Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
DE102005014936A1 (de) * 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
MY145694A (en) * 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
US20110237567A9 (en) * 2006-10-12 2011-09-29 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2073806B1 (en) * 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
US7723372B2 (en) * 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
JP5570172B2 (ja) * 2008-10-08 2014-08-13 持田製薬株式会社 喫煙による循環機能不全の予防／改善または治療剤
CN106928247A (zh) 2008-10-17 2017-07-07 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
MA34083B1 (fr) 2010-02-26 2013-03-05 Xenon Pharmaceuticals Inc Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
MD4201C1 (ro) * 2012-03-21 2013-09-30 Институт Химии Академии Наук Молдовы Procedeu de obţinere a derivaţilor carbonitrilici ai spiro[ciclopropan-oxindolilor]
MD4202C1 (ro) * 2012-03-21 2013-09-30 Институт Химии Академии Наук Молдовы Procedeu de obţinere a derivaţilor carbometoxi ai spiro[ciclopropan-oxindolilor]
JP6285969B2 (ja) * 2013-03-08 2018-02-28 ウォックハート リミテッド （２ｓ，５ｒ）−７−オキソ−６−スルホオキシ−２−［（（３ｒ）−ピペリジン−３−カルボニル）−ヒドラジノカルボニル］−１，６−ジアザ−ビシクロ［３．２．１］オクタンの調製のためのプロセス
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
EP0873309A1 (fr) 1998-10-28
NO981817L (no) 1998-04-23
PL326555A1 (en) 1998-09-28
HUP9900331A3 (en) 1999-11-29
EP0873309B1 (fr) 2002-12-18
ZA968945B (en) 1997-05-29
CN1106384C (zh) 2003-04-23
CZ126798A3 (cs) 1998-08-12
US6046341A (en) 2000-04-04
FR2740136A1 (fr) 1997-04-25
WO1997015556A1 (fr) 1997-05-01
TW474917B (en) 2002-02-01
UA59345C2 (uk) 2003-09-15
CZ295585B6 (cs) 2005-08-17
IN185328B (es) 2000-12-30
CN1202886A (zh) 1998-12-23
AU715841B2 (en) 2000-02-10
ATE229940T1 (de) 2003-01-15
DE69625517D1 (de) 2003-01-30
JPH11509232A (ja) 1999-08-17
MX9803269A (es) 1998-09-30
HUP9900331A2 (hu) 1999-05-28
JP2001302631A (ja) 2001-10-31
IS4714A (is) 1998-04-14
TR199800719T2 (xx) 1998-08-21
BR9611198A (pt) 1999-04-06
RU2167864C2 (ru) 2001-05-27
ES2191769T3 (es) 2003-09-16
KR100298925B1 (ko) 2001-09-06
NZ320352A (en) 2000-01-28
FR2740136B1 (fr) 1998-01-09
IS1949B (is) 2004-10-13
JP3274471B2 (ja) 2002-04-15
DK0873309T3 (da) 2003-03-17
NO310974B1 (no) 2001-09-24
SK49098A3 (en) 1998-09-09
MY115864A (en) 2003-09-30
EE04433B1 (et) 2005-02-15
IL124002A (en) 2002-11-10
US5994350A (en) 1999-11-30
AU7308096A (en) 1997-05-15
EE9800151A (et) 1998-12-15
SK284546B6 (sk) 2005-06-02
NO981817D0 (no) 1998-04-23
HK1016596A1 (en) 1999-11-05
KR19990067056A (ko) 1999-08-16
PL187093B1 (pl) 2004-05-31
DE69625517T2 (de) 2003-09-11

Similar Documents

Publication Publication Date Title
AR004225A1 (es) Derivados de indolin-2-ona, su uso, un procedimiento para prepararlos, composiciones farmaceuticas que los comprenden y compuestos utiles como intermediarios para preparar dichos derivados
AR050966A1 (es) Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms)
PE20220597A1 (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
AR048643A1 (es) Derivados de indol como moduladores selectivos de los receptores androgenicos (sarms)
AR057688A1 (es) CARBOXAMIDAS HETEROCíCLICAS Y SU USO EN COMPOSICIONES FUNGICIDAS.
AR109028A1 (es) Compuestos bicíclicos como plaguicidas
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
CO5590957A2 (es) Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
AR062640A1 (es) Compuestos de azolcarboxamidas y composiciones herbicidas
AR053556A1 (es) N-( 4-piridilalquil) metilsulfonamidas par combatir pestes artropodos
AR073412A1 (es) Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende.
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR084588A1 (es) Compuesto heterociclico fusionado y su uso para el control de plagas
AR048361A1 (es) Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
AR060050A1 (es) Compuestos moduladores del receptor de s1p y uso de los mismos
AR054809A1 (es) Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa
AR057987A1 (es) Compuestos agonistas de cb1 (receptor cannabinoide)
AR054799A1 (es) Derivados de oxindol
AR010651A1 (es) Un compuesto amina biciclico; una composicion insecticida, acaricida o nematocida que lo contiene; un metodo para combatir y controlar plagas de insectos, acaros o nematodos empleando dicho compuesto o composicion; y un metodo para preparar dicho compuesto
AR054083A1 (es) Compuestos imidazol y su utilizacion paar preparar medicamentos
AR065249A1 (es) Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales.
AR054813A1 (es) Derivados de pirroloquinolinas y sus usos como inhibidores de proteinas quinasas
PE20220281A1 (es) Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos
PE20010830A1 (es) Derivados de azol insecticidas o fungicidas y composiciones que los comprenden

Legal Events

Date Code Title Description
FG Grant, registration